Platinum Industries FY26: CPVC scale-up, Egypt capex, and the next growth leg

Platinum Industries closed FY26 with a strong Q4 finish and a clear expansion narrative across India and overseas. In Q4FY26, consolidated revenue from operations was INR 132.0 crore, up 36.8% year-on-year. EBITDA rose to INR 15.3 crore and PAT to INR 14.8 crore, both nearly doubling year-on-year. Standalone numbers were even sharper on revenue growth, with Q4FY26 revenue at INR 132.0 crore, up 60.4% year-on-year, and PAT of INR 15.9 crore.

For the full year, consolidated revenue stood at INR 450.4 crore, while EBITDA was INR 59.9 crore and PAT INR 51.2 crore. The year’s growth was supported by a shift in product mix and a rising contribution from CPVC. Management positioned FY26 as a transition year: scaling new capacity, broadening the portfolio, and building a platform for higher international sales.

Q4 strength, but FY26 margins show the cost of scaling

The Q4 performance showed operating leverage in action. On a consolidated basis, EBITDA margin improved to 11.6% versus 8.1% in Q4FY25, while PAT margin expanded to 12.7% from 5.8%. Standalone margins also improved year-on-year in Q4.

But at the full-year level, FY26 margins were lower than FY25. Consolidated EBITDA margin fell to 13.3% from 14.6%, and PAT margin to 11.4% from 12.6%. Standalone EBITDA margin declined to 13.9% from 16.9%, while PAT margin softened to 12.3% from 15.0%. Management linked margin volatility largely to raw material movements and a lag in passing on higher costs, particularly around March and April amid geopolitical disruptions.

CPVC is no longer a pilot, it is a meaningful revenue pillar

A key disclosure in the earnings call was the scale CPVC has reached. The CFO stated CPVC revenue in FY26 was around INR 110 crore out of INR 450 crore consolidated revenue. That places CPVC at roughly one-fourth of the topline. Elsewhere in the call, management also described the mix as roughly 30% CPVC and 70% PVC, underscoring that CPVC is now a core contributor.

Beyond the headline number, management described the CPVC opportunity as structurally attractive because CPVC applications typically require a higher stabilizer dosage than PVC. They also highlighted that CPVC manufacturing in India has been historically dominated by imported or branded compounds, while the market is gradually shifting toward domestic resin supply and more self-compounding. Platinum’s strategy is to supply the additive component into this shift.

The company also pointed to customer validation, stating that large pipe makers are already buying from them, and that their CPVC Uni Pack has NSF certification. These details matter because CPVC formulations are quality-sensitive, and credibility is a barrier to entry.

Egypt plant is the export platform bet, with defined break-even guidance

The flagship capacity initiative is the Egypt greenfield project. The investor presentation laid out a 60,000 TPA facility with capex of around INR 68 crore and highlighted location advantages: duty-free export access to the United States through QIZ, and FTA access to key South American markets.

On the conference call, management added more measurable guidance. They expect commercial operations to commence in Q3 FY27. For FY27, about 10% of topline is expected to come from Egypt, with the balance driven by India. They also stated break-even utilization is around 30% to 35%, and they expect the sales mix to be roughly 50% Egypt domestic and 50% global exports.

Management indicated revenue potential of around INR 300 crore over three years post-launch and suggested peak annual potential could be higher, though the documents do not provide a detailed ramp schedule.

Oleochemicals and life sciences are the next portfolio extension, starting with trading and CDMO

A new element in the call was oleochemicals. Management said sales began in April under a contract manufacturing model while the company runs pilot market development. For the year, they are targeting INR 55 crore to INR 60 crore in oleochemicals revenue and suggested they could reach that run-rate by the second quarter.

They also stated that after one to one-and-a-half years, the company expects to invest in its own plant for oleo-based derivatives. Separately, in a chat question, management said the life sciences division is expected to contribute to topline in the current year.

These are early-stage initiatives, and the documents do not provide segment economics or capital allocation details yet. But they indicate a deliberate plan to diversify beyond PVC and CPVC, targeting other polymers as end markets.

What investors should track from here

Management reiterated two forward targets: more than 40% revenue growth in FY27 and a 35% CAGR from FY26 to FY29. They also guided to an EBITDA margin band of 13% to 15% for FY27.

Execution will hinge on three practical milestones. First is the commissioning and ramp-up of Egypt in Q3 FY27, with clarity on export volumes and margin outcomes. Second is the completion and full utilization of the expanded Palghar facility, where CPVC is already operating but the broader capacity build-out is still underway. Third is whether the new verticals, especially oleochemicals, can scale without diluting margins or stretching working capital.

Platinum’s FY26 story is best read as a scale and portfolio transition. The company has disclosed enough near-term markers, CPVC revenue, Egypt contribution expectations, and margin guidance, for investors to validate execution over the next few quarters.